[{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Institute of Genetics and Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NXP900","moa":"YES1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Institute of Genetics and Cancer","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Institute of Genetics and Cancer"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"NXP900","moa":"YES1","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NXP900","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvectis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"NXP900","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NXP900","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nuvectis Pharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NXP900","moa":"||SRC\/YES1 kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for NXP900

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NXP900 is an oral SRC/YES1 kinase inhibitor is being investigated in combination with osimertinib (Tagrisso®) in EGFR-mutated non-small cell lung cancer (NSCLC) models.

                          Product Name : NXP900

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 05, 2025

                          Lead Product(s) : NXP900,Osimertinib Mesylate

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases is being evaluated in early-stage clinical trial in combination with Alectinib for the treatment of non-small cell lung cancer.

                          Product Name : NXP900

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 08, 2024

                          Lead Product(s) : NXP900,Alectinib Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NXP900 is a novel inhibitor of the SRC family of kinases with low nanomolar potency against YES1 and SRC. It has demonstrated robust single agent antitumor activity in several in vivo oncological xenograft models.

                          Product Name : NXP900

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 12, 2023

                          Lead Product(s) : NXP900

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NXP900 is a novel inhibitor of the SRC family of kinases with low nanomolar potency against YES1 and SRC. It has demonstrated robust single agent antitumor activity in several in vivo oncological xenograft models.

                          Product Name : NXP900

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 15, 2023

                          Lead Product(s) : NXP900

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NXP900's abilities to inhibit the SRC kinase and to cross the blood-brain barrier have been previously demonstrated, translating into potent and durable tumor growth inhibition in this preclinical model.

                          Product Name : NXP900

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 13, 2022

                          Lead Product(s) : NXP900

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          ELCC
                          Not Confirmed
                          ELCC
                          Not Confirmed

                          Details : NXP900, highly-selective SRC/YES1 inhibitor robust activity in preclinical models of TNBC with ILK loss effectively shuts down SRC-mediated signaling by inhibiting both the catalytic and scaffolding functions of SRC/YES1 kinases, without triggering immu...

                          Product Name : NXP900

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 22, 2022

                          Lead Product(s) : NXP900

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Institute of Genetics and Cancer

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank